A Rapid and Sensitive HPLC-Fluorescence Method for Determination of Mirtazapine and Its two Major Metabolites in Human Plasma

被引:0
作者
Lavasani, Hoda [1 ]
Giorgi, Mario [2 ]
Sheikholeslami, Behjat [1 ]
Hedayati, Mohammadhasan [3 ]
Rouini, Mohammad Reza [1 ,4 ]
机构
[1] Univ Tehran Med Sci, Fac Pharm, Dept Pharmaceut, Biopharmaceut & Pharmacokinet Div, Tehran, Iran
[2] Univ Pisa, Dept Vet Sci, I-56010 Pisa, Italy
[3] Sharif Univ Technol, Chem & Petr Engn Dept, Tehran, Iran
[4] Univ Tehran Med Sci, Fac Pharm, Pharmaceut Qual Assurance Res Ctr, Tehran, Iran
来源
IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH | 2014年 / 13卷 / 03期
关键词
Mirtazapine; Metabolites; HPLC; Plasma; Fluorescence; LIQUID-CHROMATOGRAPHY; ANTIDEPRESSANT MIRTAZAPINE; MAIN METABOLITES; IN-VITRO; DEMETHYL METABOLITE; MASS-SPECTROMETRY; PHARMACOKINETICS; BIOTRANSFORMATION;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A rapid and sensitive HPLC method has been developed for the quantification of mirtazapine (MRZ), a noradrenergic and specific serotonergic inhibitor antidepressant (NaSSA) and its two major metabolites N-desmethyl mirtazapine (NDM) and 8-hydroxymirtazapine (8-OHM) in human plasma. The separation was achieved using Chromolith C-18 column and a mobile phase of acetonitrile: phosphate buffer (pH = 3, 20: 80, v/v) in isocratic mode at a flow rate of 2 mL/min. A fluorescence detector was set at 290 and 350 nm for excitation and emission, respectively. Zolpidem was used as the internal standard. Liquid-liquid extraction was applied for sample clean up. All analytes were eluted in less than 5 minutes with LOQ of 1 ng/mL for MRZ and 2 ng/mL for both NDM and 8-OHM. The developed method was successfully applied to quantify MRZ and its metabolites in plasma of a healthy volunteer.
引用
收藏
页码:853 / 862
页数:10
相关论文
共 33 条
[1]   Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology [J].
Baldwin, DS ;
Anderson, IM ;
Nutt, DJ ;
Bandelow, B ;
Bond, A ;
Davidson, JRT ;
den Boer, JA ;
Fineberg, NA ;
Knapp, M ;
Scott, J ;
Wittchen, HU .
JOURNAL OF PSYCHOPHARMACOLOGY, 2005, 19 (06) :567-596
[2]   In vitro and in vivo studies on the disposition of mirtazapine in humans [J].
Dahl, ML ;
Voortman, G ;
Alm, C ;
Elwin, CE ;
Delbressine, L ;
Vos, R ;
Bogaards, JJP ;
Bertilsson, L .
CLINICAL DRUG INVESTIGATION, 1997, 13 (01) :37-46
[3]  
deBoer T, 1996, J CLIN PSYCHIAT, V57, P19
[4]   Pharmacokinetics and biotransformation of mirtazapine in human volunteers [J].
Delbressine, LPC ;
Moonen, MEG ;
Kaspersen, FM ;
Wagenaars, GN ;
Jacobs, PL ;
Timmer, CJ ;
Paanakker, JE ;
van Hal, HJM ;
Voortman, G .
CLINICAL DRUG INVESTIGATION, 1998, 15 (01) :45-55
[5]   The clinical relevance of preclinical data: Mirtazapine, a model compound [J].
Delbressine, LPC ;
Vos, RME .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1997, 17 (02) :S29-S33
[6]   In vitro metabolism of mirtazapine enantiomers by human cytochrome P450 enzymes [J].
Dodd, S ;
Boulton, DW ;
Burrows, GD ;
DeVane, CL ;
Norman, TR .
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2001, 16 (07) :541-544
[7]  
FDA CDER, 2018, GUID IND BIOAN METH
[8]  
Giorgi M., 2012, American Journal of Animal and Veterinary Sciences, V7, P42
[9]   Pharmacokinetics of mirtazapine and its main metabolites in Beagle dogs: A pilot study [J].
Giorgi, Mario ;
Yun, Hyoin .
VETERINARY JOURNAL, 2012, 192 (02) :239-241
[10]   Mirtazapine in major depression with comorbid generalized anxiety disorder [J].
Goodnick, PJ ;
Puig, A ;
DeVane, CL ;
Freund, BV .
JOURNAL OF CLINICAL PSYCHIATRY, 1999, 60 (07) :446-448